Ritvos O - Search Results

1

Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.

Nissinen TA, Hentilä J, Penna F, Lampinen A, Lautaoja JH, Fachada V, Holopainen T, Ritvos O, Kivelä R, Hulmi JJ. Nissinen TA, et al. Among authors: ritvos o. J Cachexia Sarcopenia Muscle. 2018 Jun;9(3):514-529. doi: 10.1002/jcsm.12310. Epub 2018 May 2. J Cachexia Sarcopenia Muscle. 2018. PMID: 29722201 Free PMC article.

2

Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.

Hoogaars WM, Mouisel E, Pasternack A, Hulmi JJ, Relizani K, Schuelke M, Schirwis E, Garcia L, Ritvos O, Ferry A, 't Hoen PA, Amthor H. Hoogaars WM, et al. Among authors: ritvos o. Hum Gene Ther. 2012 Dec;23(12):1269-79. doi: 10.1089/hum.2012.056. Epub 2012 Sep 24. Hum Gene Ther. 2012. PMID: 22894762

3

Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins.

Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WM, Ma H, Pierre P, Pasternack A, Kainulainen H, Ritvos O. Hulmi JJ, et al. Among authors: ritvos o. Am J Physiol Endocrinol Metab. 2013 Jan 1;304(1):E41-50. doi: 10.1152/ajpendo.00389.2012. Epub 2012 Oct 31. Am J Physiol Endocrinol Metab. 2013. PMID: 23115080 Free article.

4

Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.

Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WM, Pasternack A, Kainulainen H, Ritvos O. Hulmi JJ, et al. Among authors: ritvos o. Am J Physiol Endocrinol Metab. 2013 Jul 15;305(2):E171-82. doi: 10.1152/ajpendo.00065.2013. Epub 2013 May 21. Am J Physiol Endocrinol Metab. 2013. PMID: 23695214 Free article.

5

Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.

Kainulainen H, Papaioannou KG, Silvennoinen M, Autio R, Saarela J, Oliveira BM, Nyqvist M, Pasternack A, 't Hoen PA, Kujala UM, Ritvos O, Hulmi JJ. Kainulainen H, et al. Among authors: ritvos o. Mol Cell Endocrinol. 2015 Jan 5;399:131-42. doi: 10.1016/j.mce.2014.10.001. Epub 2014 Oct 7. Mol Cell Endocrinol. 2015. PMID: 25304272

6

Upregulation of activin-B and follistatin in pulmonary fibrosis - a translational study using human biopsies and a specific inhibitor in mouse fibrosis models.

Myllärniemi M, Tikkanen J, Hulmi JJ, Pasternack A, Sutinen E, Rönty M, Leppäranta O, Ma H, Ritvos O, Koli K. Myllärniemi M, et al. Among authors: ritvos o. BMC Pulm Med. 2014 Nov 1;14:170. doi: 10.1186/1471-2466-14-170. BMC Pulm Med. 2014. PMID: 25361680 Free PMC article.

7

Effects of muscular dystrophy, exercise and blocking activin receptor IIB ligands on the unfolded protein response and oxidative stress.

Hulmi JJ, Hentilä J, DeRuisseau KC, Oliveira BM, Papaioannou KG, Autio R, Kujala UM, Ritvos O, Kainulainen H, Korkmaz A, Atalay M. Hulmi JJ, et al. Among authors: ritvos o. Free Radic Biol Med. 2016 Oct;99:308-322. doi: 10.1016/j.freeradbiomed.2016.08.017. Epub 2016 Aug 20. Free Radic Biol Med. 2016. PMID: 27554968

8

Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes.

Nissinen TA, Degerman J, Räsänen M, Poikonen AR, Koskinen S, Mervaala E, Pasternack A, Ritvos O, Kivelä R, Hulmi JJ. Nissinen TA, et al. Among authors: ritvos o. Sci Rep. 2016 Sep 26;6:32695. doi: 10.1038/srep32695. Sci Rep. 2016. PMID: 27666826 Free PMC article.

9

Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.

Puolakkainen T, Ma H, Kainulainen H, Pasternack A, Rantalainen T, Ritvos O, Heikinheimo K, Hulmi JJ, Kiviranta R. Puolakkainen T, et al. Among authors: ritvos o. BMC Musculoskelet Disord. 2017 Jan 19;18(1):20. doi: 10.1186/s12891-016-1366-3. BMC Musculoskelet Disord. 2017. PMID: 28103859 Free PMC article.

10

Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.

Hulmi JJ, Nissinen TA, Räsänen M, Degerman J, Lautaoja JH, Hemanthakumar KA, Backman JT, Ritvos O, Silvennoinen M, Kivelä R. Hulmi JJ, et al. Among authors: ritvos o. J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):417-432. doi: 10.1002/jcsm.12265. Epub 2017 Dec 11. J Cachexia Sarcopenia Muscle. 2018. PMID: 29230965 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

136 results

Search Page